Employment |
No Relationships to Disclose |
|
|
Leadership |
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests |
No Relationships to Disclose |
|
|
Honoraria |
Company: BluPrint Oncology |
Recipient: You |
Company: PER |
Recipient: You |
Company: CurioScience |
Recipient: You |
|
Consulting or Advisory Role |
Company: AstraZeneca |
Recipient: You |
Company: Clovis Oncology |
Recipient: You |
Company: GOG Foundation |
Recipient: You |
Company: Merck |
Recipient: You |
Company: Rubius Therapeutics |
Recipient: You |
Company: Myriad Genetics |
Recipient: You |
Company: Genentech/Roche |
Recipient: You |
Company: Seagen |
Recipient: You |
Company: Eisai |
Recipient: You |
Company: Novocure |
Recipient: You |
Company: Aadi Biosciences |
Recipient: You |
Company: On Target Laboratories |
Recipient: You |
Company: Immunogen |
Recipient: You |
Company: Mersana |
Recipient: You |
Company: Caris Life Sciences |
Recipient: You |
|
Speakers' Bureau |
Company: Genmab/Seagen |
Recipient: You |
Company: AstraZeneca |
Recipient: You |
Company: AstraZeneca |
Recipient: You |
|
Research Funding |
Company: Merck |
Recipient: Your Institution |
Company: Akeso Biopharma |
Recipient: Your Institution |
Company: GEICO |
Recipient: Your Institution |
Company: Karyopharm Therapeutics |
Recipient: Your Institution |
Company: GOG Foundation |
Recipient: Your Institution |
Company: Acrivon Therapeutics |
Recipient: Your Institution |
Company: Zentalis |
Recipient: Your Institution |
Company: Regeneron |
Recipient: Your Institution |
Company: Adaptimmune |
Recipient: Your Institution |
Company: Mersana |
Recipient: Your Institution |
|
Patents, Royalties, Other Intellectual Property |
No Relationships to Disclose |
|
|
Expert Testimony |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses |
Company: AstraZeneca |
Recipient: You |
Company: Seagen |
Recipient: You |
Company: Genmab |
Recipient: You |
Company: GOG Foundation |
Recipient: You |
|
Other Relationship |
No Relationships to Disclose |
|
|
(OPTIONAL) Uncompensated Relationships |
not answered |
|
|
(OPTIONAL) Open Payments Link |
not answered |
|
|